Impact of site of occlusion in proximal splenic artery embolisation for blunt splenic trauma.
Journal
CVIR endovascular
ISSN: 2520-8934
Titre abrégé: CVIR Endovasc
Pays: Switzerland
ID NLM: 101738484
Informations de publication
Date de publication:
20 Aug 2022
20 Aug 2022
Historique:
received:
05
04
2022
accepted:
29
07
2022
entrez:
20
8
2022
pubmed:
21
8
2022
medline:
21
8
2022
Statut:
epublish
Résumé
Proximal splenic artery embolisation (PSAE) can be performed in stable patients with Association for the Surgery of Trauma (AAST) grade III-V splenic injury. PSAE reduces splenic perfusion but maintains viability of the spleen and pancreas via the collateral circulation. The hypothesized ideal location is between the dorsal pancreatic artery (DPA) and great pancreatic artery (GPA). This study compares the outcomes resulting from PSAE embolisation in different locations along the splenic artery. Retrospective review was performed of PSAE for blunt splenic trauma (2015-2020). Embolisation locations were divided into: Type I, proximal to DPA; Type II, DPA-GPA; Type III, distal to GPA. Fifty-eight patients underwent 59 PSAE: Type I (7); Type II (27); Type III (25). Data was collected on technical and clinical success, post-embolisation pancreatitis and splenic perfusion. Statistical significance was assessed using a chi-squared test. Technical success was achieved in 100% of cases. Clinical success was 100% for Type I/II embolisation and 88% for Type III: one patient underwent reintervention and two had splenectomies for ongoing instability. Clinical success was significantly higher in Type II embolisation compared to Type III (p = 0.02). No episodes of pancreatitis occurred post-embolisation. Where post-procedural imaging was obtained, splenic perfusion remained 100% in Type I and II embolisation and 94% in Type III. Splenic perfusion was significantly higher in the theorized ideal Type II group compared to Type I and III combined (p = 0.01). The results support the proposed optimal embolisation location as being between the DPA and GPA.
Sections du résumé
BACKGROUND
BACKGROUND
Proximal splenic artery embolisation (PSAE) can be performed in stable patients with Association for the Surgery of Trauma (AAST) grade III-V splenic injury. PSAE reduces splenic perfusion but maintains viability of the spleen and pancreas via the collateral circulation. The hypothesized ideal location is between the dorsal pancreatic artery (DPA) and great pancreatic artery (GPA). This study compares the outcomes resulting from PSAE embolisation in different locations along the splenic artery.
MATERIALS AND METHODS
METHODS
Retrospective review was performed of PSAE for blunt splenic trauma (2015-2020). Embolisation locations were divided into: Type I, proximal to DPA; Type II, DPA-GPA; Type III, distal to GPA. Fifty-eight patients underwent 59 PSAE: Type I (7); Type II (27); Type III (25). Data was collected on technical and clinical success, post-embolisation pancreatitis and splenic perfusion. Statistical significance was assessed using a chi-squared test.
RESULTS
RESULTS
Technical success was achieved in 100% of cases. Clinical success was 100% for Type I/II embolisation and 88% for Type III: one patient underwent reintervention and two had splenectomies for ongoing instability. Clinical success was significantly higher in Type II embolisation compared to Type III (p = 0.02). No episodes of pancreatitis occurred post-embolisation. Where post-procedural imaging was obtained, splenic perfusion remained 100% in Type I and II embolisation and 94% in Type III. Splenic perfusion was significantly higher in the theorized ideal Type II group compared to Type I and III combined (p = 0.01).
CONCLUSION
CONCLUSIONS
The results support the proposed optimal embolisation location as being between the DPA and GPA.
Identifiants
pubmed: 35986797
doi: 10.1186/s42155-022-00315-0
pii: 10.1186/s42155-022-00315-0
pmc: PMC9391208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
43Informations de copyright
© 2022. The Author(s).
Références
J Vasc Interv Radiol. 2008 May;19(5):652-6
pubmed: 18440451
Am J Surg. 2005 Mar;189(3):335-9
pubmed: 15792763
Cardiovasc Intervent Radiol. 2011 Jun;34(3):522-31
pubmed: 20700592
Am J Emerg Med. 2020 Sep;38(9):1710-1714
pubmed: 32721782
Cardiovasc Intervent Radiol. 2011 Oct;34(5):1069-73
pubmed: 21431965
J Trauma. 2000 Aug;49(2):177-87; discussion 187-9
pubmed: 10963527
Radiology. 1991 Oct;181(1):189-96
pubmed: 1887032
West J Emerg Med. 2020 May 22;21(4):819-822
pubmed: 32726250
J Vasc Interv Radiol. 2012 Jul;23(7):976-9
pubmed: 22720897
Mil Med Res. 2017 May 30;4:17
pubmed: 28573044
AJR Am J Roentgenol. 2015 Oct;205(4):720-5
pubmed: 26397320
Ann R Coll Surg Engl. 2017 Jan;99(1):82-87
pubmed: 27490986
J Trauma. 2007 Jun;62(6):1481-6
pubmed: 17563670
Eur Radiol. 2004 Sep;14(9):1718-9
pubmed: 14963688
Semin Intervent Radiol. 2012 Jun;29(2):147-9
pubmed: 23729986
Am J Surg. 2005 Aug;190(2):273-8
pubmed: 16023445
J Trauma. 2011 Jan;70(1):252-60
pubmed: 21217497
Am Surg. 2003 Dec;69(12):1036-9; discussion 1039-40
pubmed: 14700287
J Trauma Acute Care Surg. 2017 Nov;83(5):934-943
pubmed: 29068875
Urol Int. 2011;87(1):59-63
pubmed: 21701137
Ann R Coll Surg Engl. 2009 May;91(4):W6-11
pubmed: 19416579
Br J Radiol. 2009 Jan;82(973):e11-4
pubmed: 19095808
Open Med (Wars). 2016 Aug 2;11(1):307-315
pubmed: 28352813
Clin Anat. 2003 Sep;16(5):371-7
pubmed: 12903057
Surgery. 1979 May;85(5):530-3
pubmed: 432814
J Trauma Acute Care Surg. 2013 Jul;75(1):69-74; discussion 74-5
pubmed: 23778441
J Vasc Interv Radiol. 2001 Feb;12(2):209-14
pubmed: 11265885
Cardiovasc Intervent Radiol. 2018 Sep;41(9):1324-1332
pubmed: 29671059
Radiology. 1977 Oct;125(1):95-102
pubmed: 897195
World J Gastrointest Surg. 2020 Feb 27;12(2):55-67
pubmed: 32128029
Semin Intervent Radiol. 2020 Mar;37(1):97-102
pubmed: 32139975
J Trauma Acute Care Surg. 2018 Dec;85(6):1119-1122
pubmed: 30462622
Eur J Trauma Emerg Surg. 2009 Apr;35(2):108
pubmed: 26814762
CVIR Endovasc. 2020 Dec 7;3(1):92
pubmed: 33283253
J Trauma Acute Care Surg. 2012 May;72(5):1127-34
pubmed: 22673236
CVIR Endovasc. 2019 Mar 18;2(1):11
pubmed: 32026033